|[December 19, 2013]
Tryton Medical Establishes Bifurcation Institute
DURHAM, N.C. --(Business Wire)--
Tryton Medical, Inc., the leading developer of stents designed to treat
bifurcation lesions, today announced the launch of the Bifurcation
Institute. The Bifurcation Institute is a comprehensive education
resource established to advance the standard of care for bifurcated
coronary artery disease, a common, and often untreated, clinical need.
in the Bifurcation Institute is free and provides physicians access to
e-newsletters summarizing recent clinical data and news, links to timely
webcasts and a Case
Library that highlights the latest techniques and tips when treating
bifurcation disease. Clinical symposia and educational workshops will be
offered through the Bifurcation Institute.
"There s a significant unmet need for education and training regarding
bifurcations. In patients undergoing PCI (News - Alert)-stenting, approximately
one-third has a bifurcation lesion. Left main disease, an accumulation
of plaque that narrows the base of the coronary tree, is a persistent
challenge in interventional cardiology, as more than 75 percent of left
main lesions are bifurcation lesions. The Bifurcation Institute aims to
evolve treatment patterns and current procedural guidance to incorporate
safe and effective treatment of bifurcations in daily practice," said
Dr. Maciej Lesiak, who is chief of the catheterization laboratory at the
Karol Marcinkowski University of Medical Sciences in Poznan, Poland. On
March 5-6, 2014, Dr. Lesiak and his institution will host the inaugural
Bifurcation Institute workshop focusing on the clinical outcomes and
treatment of bifurcation lesions with the Tryton Side Branch Stent.
The Bifurcation Institute features the results
of the landmark Tryton IDE trial presented in a late-breaking
clinical trial session at TCT 2013.
"Tryton Medical is pleased to offer the Bifurcation Institute, which
expands our commitment to physician education and training worldwide,"
said Shawn McCarthy, CEO of Tryton Medical. "It is our intent that the
Bifurcation Institute will become the preferred resource for physicians
providing evidence-based care to patients with complex bifurcation
About Coronary Bifurcation Disease
Coronary artery disease often results in the buildup of plaque at the
site of a bifurcation, where one artery branches from another. Current
approaches to treating these lesions are time consuming and technically
difficult. As a result, the side branch is often left unstented, leaving
it vulnerable to higher rates of restenosis, the re-narrowing of the
stented vessel following implantation.
About Tryton Medical, Inc.
Tryton Medical, Inc., located in Durham, N.C., is the leading developer
of novel stent systems for the treatment of bifurcation lesions. The
company was founded in 2003 by Aaron V. Kaplan, M.D. (professor of
medicine at Dartmouth Medical School/Dartmouth- Hitchcock Medical
Center) and Dan Cole, General Partner at Spray Ventures. Privately held,
Tryton is backed by PTV Sciences, RiverVest Venture Partners, Spray
Venture Partners, and the 3x5 Special Opportunity Fund. For more
information please visit www.trytonmedical.com
and follow the company on Twitter (News - Alert) at @TrytonMedical1.
[ Back To Technology News's Homepage ]